@higgybear20's tirzepatide confusion, fact-checked

What did @higgybear20 actually say?

The creator says she switched from compounded semaglutide to tirzepatide after a blood test showed elevated B12 levels, which she attributes to B12 being mixed into her compounded semaglutide. After eight weeks on tirzepatide, she reports zero weight loss, persistent cravings, and reduced appetite suppression compared to semaglutide. Her takeaway: "tirzepatide is supposed to work better" and "stronger," but it simply hasn't for her.

She also mentions her hypoglycemia improved on tirzepatide, though not as dramatically as it did on semaglutide. She's asking whether others have had the same experience and whether switching back makes sense. This is a genuine patient experience worth examining, because several of the assumptions embedded in it are only partly supported by the evidence.

Does the science back this up?

Tirzepatide does outperform semaglutide on average in head-to-head trials, but "on average" is doing a lot of work in that sentence. Individual response varies significantly, and eight weeks is genuinely early to draw conclusions.

The SURMOUNT-5 trial (Jastreboff et al., 2025, NEJM) compared tirzepatide 10mg or 15mg directly against semaglutide 2.4mg in adults with obesity. Tirzepatide produced about 20.2% body weight reduction versus 13.7% for semaglutide over 72 weeks. That is a meaningful population-level difference. However, the trial also showed substantial individual variation, meaning a subset of participants responded better to semaglutide or showed minimal response to tirzepatide.

Tirzepatide's dual agonism of GIP and GLP-1 receptors is the proposed mechanism for its stronger average effect (Nauck and D'Alessio, 2022, Nature Reviews Endocrinology). But GIP receptor expression and sensitivity vary between individuals, which may partly explain why some people find tirzepatide less effective for appetite suppression than semaglutide.

What did they get wrong (or right)?

She got the general hierarchy right: tirzepatide does outperform semaglutide in population-level studies. Credit where it's due. But the framing that it should automatically work better for every individual is where the logic breaks down.

On the B12 issue: elevated B12 from compounded semaglutide with added B12 is a real clinical consideration, but it's worth noting that high serum B12 alone is rarely the primary reason to switch medications. B12 toxicity from supplementation is uncommon, and most practitioners would first remove the B12 additive rather than discontinue the GLP-1 entirely. The creator's doctor may have had other reasons, but as presented, this explanation is incomplete.

Her hypoglycemia claim also deserves scrutiny. Neither semaglutide nor tirzepatide are approved treatments for hypoglycemia in people without diabetes. GLP-1 receptor agonists can modulate glucose levels, but characterizing improvement in hypoglycemia symptoms as a primary therapeutic effect of these drugs goes beyond what the current evidence supports for non-diabetic users.

Eight weeks is also short. Dose titration for tirzepatide typically runs 4 to 20 weeks before patients reach an effective maintenance dose, and clinical response at week eight does not predict week 24 outcomes reliably.

What should you actually know?

Individual variation in GLP-1 response is real and documented. A 2023 analysis by Rubino et al. in Obesity found that roughly 10 to 15 percent of semaglutide users are "low responders" at standard doses. Similar patterns are likely with tirzepatide, though the data is less mature.

If you switch GLP-1 medications and see no effect after eight weeks, the most evidence-consistent questions to ask your prescriber are: Have I reached an adequate dose? Is my thyroid function (relevant given her Hashimoto's hashtag) optimized, since hypothyroidism can blunt weight loss response? Are there absorption or adherence factors at play?

On compounded GLP-1s specifically: compounded semaglutide and tirzepatide are not equivalent to FDA-approved branded versions. Potency, purity, and additives like B12 or B6 vary by compounding pharmacy. The FDA has flagged this repeatedly. If your compounded version includes additives you didn't specifically request or discuss, that is a conversation to have with your prescriber before switching drugs entirely.

Finally, switching back to a medication that worked is a legitimate clinical option. That is not bad advice. But doing so without understanding why tirzepatide underperformed means you may hit the same wall again later.